1. Home
  2. CDNA vs NNNN Comparison

CDNA vs NNNN Comparison

Compare CDNA & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CareDx Inc.

CDNA

CareDx Inc.

HOLD

Current Price

$24.08

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo Anbio Biotechnology Class A Ordinary Shares

NNNN

Anbio Biotechnology Class A Ordinary Shares

N/A

Current Price

$14.88

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CDNA
NNNN
Founded
1998
2021
Country
United States
Germany
Employees
N/A
27
Industry
Medical Specialities
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.2B
IPO Year
2007
N/A

Fundamental Metrics

Financial Performance
Metric
CDNA
NNNN
Price
$24.08
$14.88
Analyst Decision
Buy
Analyst Count
6
0
Target Price
$28.00
N/A
AVG Volume (30 Days)
652.3K
17.5K
Earning Date
04-28-2026
04-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.05
N/A
Revenue
$48,324,000.00
N/A
Revenue This Year
$16.01
N/A
Revenue Next Year
$11.31
N/A
P/E Ratio
$469.20
$446.57
Revenue Growth
18.93
N/A
52 Week Low
$10.96
$8.59
52 Week High
$24.02
$55.65

Technical Indicators

Market Signals
Indicator
CDNA
NNNN
Relative Strength Index (RSI) 65.75 28.52
Support Level $15.80 $10.50
Resistance Level N/A $31.12
Average True Range (ATR) 1.04 3.79
MACD 0.09 -1.99
Stochastic Oscillator 93.00 5.17

Price Performance

Historical Comparison
CDNA
NNNN

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).

Share on Social Networks: